Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Gastrointestinal stromal tumor: 5 years later.

van der Zwan SM, DeMatteo RP.

Cancer. 2005 Nov 1;104(9):1781-8. Review.

2.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD.

Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Review.

PMID:
11740803
3.

Molecular research directions in the management of gastrointestinal stromal tumors.

Tarn C, Godwin AK.

Curr Treat Options Oncol. 2005 Nov;6(6):473-86. Review.

PMID:
16242052
5.

Pathology of gastrointestinal stromal tumors.

Hirota S, Isozaki K.

Pathol Int. 2006 Jan;56(1):1-9. Review.

PMID:
16398673
6.

Gastrointestinal stromal tumor.

Gupta P, Tewari M, Shukla HS.

Surg Oncol. 2008 Aug;17(2):129-38. doi: 10.1016/j.suronc.2007.12.002. Review.

PMID:
18234489
7.

Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.

Cirocchi R, Farinella E, La Mura F, Cavaliere D, Avenia N, Verdecchia GM, Giustozzi G, Noya G, Sciannameo F.

Tumori. 2010 May-Jun;96(3):392-9. Review.

8.

Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.

Eisenberg BL.

Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S24-9. Review.

PMID:
17101065
9.

Gastrointestinal stromal tumors and the evolution of targeted therapy.

Sanborn RE, Blanke CD.

Clin Adv Hematol Oncol. 2005 Aug;3(8):647-57. Review.

PMID:
16167051
10.

[Current aspects of treatment in gastrointestinal stromal tumors (GIST)].

Láng I, Hitre E.

Orv Hetil. 2005 May 1;146(18 Suppl 1):935-41. Review. Hungarian.

PMID:
15921308
11.

Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.

Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B.

Oncologist. 2006 Jan;11(1):9-20. Review.

12.

[Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].

Shiba K, Matsumoto T, Hirota S.

Gan To Kagaku Ryoho. 2009 Jul;36(7):1080-5. Review. Japanese.

PMID:
19620796
13.

Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.

Sawaki A, Yamao K.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S44-9. Review.

PMID:
15309514
14.

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.

Eisenberg BL, Judson I.

Ann Surg Oncol. 2004 May;11(5):465-75. Review.

PMID:
15123459
15.

Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.

Heinrich MC, Corless CL.

J Surg Oncol. 2005 Jun 1;90(3):195-207; discussion 207. Review.

PMID:
15895440
17.

Gastrointestinal stromal tumors: a paradigm for therapeutic options in solid organ tumors.

Novak C, Trevino JG.

Mini Rev Med Chem. 2010 Jun;10(7):624-34. Review.

PMID:
20500152
18.

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

Lasota J, Miettinen M.

Semin Diagn Pathol. 2006 May;23(2):91-102. Review.

PMID:
17193822
19.

Imatinib: a review of its use in the management of gastrointestinal stromal tumours.

Siddiqui MA, Scott LJ.

Drugs. 2007;67(5):805-20. Review.

PMID:
17385949
20.

[Surgical treatment of an advanced GIST the age of imatinib].

Fernández JA, Parrilla P.

Cir Esp. 2009 Jul;86(1):3-12. doi: 10.1016/j.ciresp.2008.09.023. Review. Spanish.

Supplemental Content

Support Center